, Tracking Stock Market Picks
Enter Symbol:
Cardium Therapeutics Inc. (CRXM) [hlAlert]

down 99.11 %

Cardium Therapeutics Inc. (CXM) rated Buy with price target $5 by Lazard Capital

Posted on: Friday,  May 2, 2008  8:25 AM ET by Lazard Capital

Lazard Capital rated Buy Cardium Therapeutics Inc. (OTCBB: CRXM) on 05/02/2008, when the stock price was $44.00. Since
then, Cardium Therapeutics Inc. has lost 99.11% as of 08/27/2015's recent price of $0.39.
If you would have followed this Lazard Capital's recommendation on CRXM, you would have lost 99.11% of your investment in 2673 days.

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium?s lead product candidate, Generx (alferminogene tadenovec, Ad5FGF4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina.

Lazard Capital Markets’ research team is broadly recognized for its insight, thoroughness, and objectivity. Our goal is to help our clients make the best-informed decisions by providing timely, thoughtful analysis as well as access to company management teams and industry thought leaders. Our industry-focused analysts strive to identify emerging sector trends as well as bottom-up fundamental issues affecting their stocks under coverage. We add value by conducting extensive primary survey work, hosting proprietary events, cultivating industry contacts, and participating in relevant industry conferences.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/2/2008 8:25 AM Buy
44.00 100.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy